{"protocolSection": {"identificationModule": {"nctId": "NCT00852631", "orgStudyIdInfo": {"id": "D1443L00060"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Seroquel XR in Adults With Schizophrenia", "officialTitle": "Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia"}, "statusModule": {"statusVerifiedDate": "2012-05", "overallStatus": "TERMINATED", "whyStopped": "The study was prematurely terminated due to insufficient recruitment.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-26", "studyFirstSubmitQcDate": "2009-02-26", "studyFirstPostDateStruct": {"date": "2009-02-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-05-18", "resultsFirstSubmitQcDate": "2012-06-12", "resultsFirstPostDateStruct": {"date": "2012-07-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-06-12", "lastUpdatePostDateStruct": {"date": "2012-07-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days."}, "conditionsModule": {"conditions": ["Schizophrenia"], "keywords": ["Quetiapine efficacy in schizophrenia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "Quetiapine fumarate (Seroquel)", "description": "600mg Extended release tablet, oral, once daily", "otherNames": ["Seroquel XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Positive and Negative Syndrome Scale (PANSS) Total Score", "description": "Change in Positive and Negative Syndrome Scale Total Score from Day 1 (baseline) to Day 42 (final visit) or withdrawal. Minimum value of total PANSS is 30 , Maximum is 210.\n\nMinimum value considered better is score decreased from baseline at least 30%.", "timeFrame": "From Day 1 (baseline) to Day 42"}], "secondaryOutcomes": [{"measure": "Change in Clinical Global Impression - Severity of Illness (CGI-S) Score", "description": "Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \\> 1 score.", "timeFrame": "From Day 1 (Baseline) to Day 42"}, {"measure": "Clinical Global Impression - Severity of Illness (CGI-S) Score", "description": "Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \\> 1 score.", "timeFrame": "Day 14"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient meets the DSM-IV criteria for schizophrenia\n* Patient has a PANSS total score \u2265 70 at baseline\n* Patient has a CGI-S score of \u2265 4(moderately ill) at baseline\n* Patient is healthy on the basis of physical examination and vital signs at baseline\n\nExclusion Criteria:\n\n* Positive urine drug screen for Opiates, amphetamine, barbiturate, cocaine, cannabis, or ecstasy abuse\n* Has history of neuroleptic malignant syndrome, seropositive for anti-HIV, hepatitis B or C virus antigen\n* Patient with unstable or inadequately treated Diabetes Mellitus\n* Use of potent cytochrome P450 inhibitors or inducer within 14 days before baseline", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Thawatchai Leelahanaj, MD", "affiliation": "Phramongkutklao Hospital, Bangkok, Thailand", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Chiang Mai", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "Research Site", "city": "Songkla", "country": "Thailand", "geoPoint": {"lat": 7.19882, "lon": 100.5951}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "On Day 1, baseline assessments will be performed, and patients will be assigned to Seroquel XR at 300 mg. On Day 2 all patients are assigned to reach target dose of Seroquel XR at 600 mg. Administration of study medication continue with Seroquel XR 600 mg daily until Day 42. Each visit will have \u00b1 3 days window period.", "recruitmentDetails": "Patients provide informed consent and are screened for eligibility (at Visit 1) up to 7 days before baseline assessment on Day 1.", "groups": [{"id": "FG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEDIAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43", "spread": "39.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Change in Clinical Global Impression - Severity of Illness (CGI-S) Score", "description": "Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \\> 1 score.", "populationDescription": "The number of patient at Day 42 (n= 17) is different than at Baseline (n= 28), because some of them withdraw/terminate during the study.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-05", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From Day 1 (Baseline) to Day 42", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"title": "Day 1 (Baseline) (n= 28)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "0.7"}]}]}, {"title": "Day 42 (n= 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "1.1"}]}]}]}, {"type": "PRIMARY", "title": "Change in Positive and Negative Syndrome Scale (PANSS) Total Score", "description": "Change in Positive and Negative Syndrome Scale Total Score from Day 1 (baseline) to Day 42 (final visit) or withdrawal. Minimum value of total PANSS is 30 , Maximum is 210.\n\nMinimum value considered better is score decreased from baseline at least 30%.", "populationDescription": "The number of patient at Day 42 (n= 17) is different than at Baseline (n= 28), because some of them withdraw/terminate during the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From Day 1 (baseline) to Day 42", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"title": "Day 1 (Baseline) (n= 28)", "categories": [{"measurements": [{"groupId": "OG000", "value": "85.3", "spread": "28.8"}]}]}, {"title": "Day 42 (n= 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.5", "spread": "28.6"}]}]}]}, {"type": "SECONDARY", "title": "Clinical Global Impression - Severity of Illness (CGI-S) Score", "description": "Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \\> 1 score.", "populationDescription": "The number of patient is different, because some of them withdraw/terminate during the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Day 14", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "1.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Seroquel XR", "description": "Seroquel XR 300mg on day 1, 600mg from day 2 onwards. The treatment period will take 6 weeks or 42 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 28, "otherNumAffected": 14, "otherNumAtRisk": 28}], "seriousEvents": [{"term": "Seizure", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 28}]}], "otherEvents": [{"term": "Dry Mouth", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 28}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 28}]}, {"term": "Stiff nose", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "clinicaltrialtransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Modulated", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}